By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

bioTheranostics 

11025 Roselle Street
Suite 200
San Diego  California  92121  U.S.A.
Phone: 858-587-5870 Fax: 858-587-5871


SEARCH JOBS








Company News
bioTheranostics Appoints Industry Veteran Don Hardison To Board Of Directors 7/20/2016 8:52:36 AM
ASCO2016: bioTheranostics Release: New Data Presented At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting Expand Clinical Utility Of Breast Cancer Index(SM) In The Extended Adjuvant Setting To Include Early-Stage, ER+ Patients With Up To Three Positive Nodes 6/6/2016 12:30:57 PM
ASCO2016: Study Presented At ASCO 2016 Shows Clinical Utility Of bioTheranostics’ Cancertype ID In Predicting Tumor Type & Aiding In Treatment Optimization For Metastatic Cancer Patients 6/3/2016 8:35:37 AM
bioTheranostics Release: Clinical Cancer Research Publishes Study Demonstrating Clinically Meaningful And Statistically Significant Prognostic Improvement By The Breast Cancer Index(SM) Over Oncotype DX In Early-Stage, Estrogen Receptor-Positive, Lymph Node-Negative Breast Cancer Patients 6/3/2016 6:28:52 AM
Study Supports Diagnostic Utility Of bioTheranostics’ CancerTYPE ID Molecular Cancer Classifier In Cytology & Limited Tissue Samples 5/19/2016 10:56:39 AM
bioTheranostics' Chief Scientific Officer Nominated For Athena Pinnacle Award 4/29/2016 10:23:34 AM
bioTheranostics To Present Feasibility Data Of Gene Expression Profiling In Blood 4/19/2016 12:03:31 PM
SoCal's bioTheranostics Rakes In $32 Million for Cancer Diagnostics 1/21/2016 6:55:09 AM
bioTheranostics Release: Studies Demonstrate Broadening Clinical Utility Of Biotheranostics’ Breast Cancer Index Molecular Test In The Extended Endocrine Therapy Setting 12/8/2015 1:22:49 PM
Yale University Study Shows bioTheranostics’ Breast Cancer Indexsm Molecular Test Impacts Extended Endocrine Therapy Decisions In Clinical Practice 12/8/2015 12:44:16 PM
12345
//-->